From bosentan to macitentan for pulmonary arterial hypertension and adult congenital heart disease: Further improvement?

Int J Cardiol. 2017 Jan 15:227:51-52. doi: 10.1016/j.ijcard.2016.11.211. Epub 2016 Nov 9.

Authors

Ilja M Blok¹, Annelieke C M J van Riel¹, Arie P J van Dijk², Barbara J M Mulder¹, Berto J Bouma³

Affiliations

¹ Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands; NLHI - Netherlands Heart Institute, Utrecht, The Netherlands.
² Department of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands.
³ Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands. Electronic address: b.j.bouma@amc.nl.

PMID: 27846462
DOI: 10.1016/j.ijcard.2016.11.211

No abstract available

Keywords: Bosentan; Congenital heart disease; Macitentan; Pulmonary arterial hypertension.

Publication types

Letter
Multicenter Study
Observational Study

MeSH terms

Adult
Antihypertensive Agents / therapeutic use
Bosentan
Cohort Studies
Drug Substitution / trends*
Female
Follow-Up Studies
Heart Defects, Congenital / diagnosis
Heart Defects, Congenital / drug therapy*
Humans
Hypertension, Pulmonary / diagnosis
Hypertension, Pulmonary / drug therapy*
Male
Middle Aged
Prospective Studies
Pyrimidines / therapeutic use*
Sulfonamides / therapeutic use*

Substances

Antihypertensive Agents
Pyrimidines
Sulfonamides
Bosentan
macitentan